Summary
Fifteen patients received irradiation after combined chemotherapy with high-dose busulfan followed by autologous or allogeneic bone marrow transplantation. Of nine patients irradiated between day 30 and day 70 after their engraftment, seven developed an increased radiation response in the skin: four showed enhanced reactions during irradiation, and three had a total or severe definitive alopecia more than 16 months after CNS irradiation. Six patients were irradiated after day 70; they had either normal reactions or none at all within the cutaneous radiation portals. The possibility that busulfan might be a radiosensitizer is raised.
Similar content being viewed by others
References
Adam BA, Rokiah I, Sivanesan S (1980) Busulfan hyperpigmentation: light and electron microscopic studies. J Dermatol (Tokyo) 7: 405–411
Aristizabol SA, Manning MR, Miller RC (1979) Combined radiation adriamycin effects on human skin. In: Vaeth JM (ed) Frontiers of radiation therapy in oncology. University Park Press Baltimore, p 103
Dosik H, Hurewitz DJ, Rosner F, Schwartz JM (1970) Bullous eruption and elevated leukocyte alkaline phosphatase in the course of busulfan-treated chronic granulocytic leukemia. Blood 35: 543–548
Hymes SR, Simonton SC, Farmer ER, Beschorner WB, Tutschka PJ, Santos GW (1985) Cutaneous busulfan effects in patients receiving bone marrow transplantation. J Cutan Pathol 12: 125–129
Kyle RA, Dameshek W (1964) Porphyria cutanea tarda associated with chronic granulocytic leukemia treated with busulfan (Myleran). Blood 23: 776–785
Kyle RA, Schwartz RS, Oliner HL, Dameshek W (1961) A syndrome resembling adrenal cortical insufficiency associated with long term busulfan (Myleran) therapy. Blood 18: 497–510
Phillips TL (1980) Tissue toxicity of radiation-drug interactions, in radiation-drug interactions in the treatment of cancer. Wiley, New York, pp 175–200
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vassal, G., Hartmann, O., Habrand, J.L. et al. Enhanced cutaneous radiation effects following high-dose busulfan therapy. Cancer Chemother. Pharmacol. 23, 117–118 (1989). https://doi.org/10.1007/BF00273529
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00273529